MTA-SE Cardiovascular Imaging Research Group, Heart and Vascular Center, Semmelweis University, 68 Varosmajor Street, 1122, Budapest, Hungary.
Eur Radiol. 2017 Nov;27(11):4538-4543. doi: 10.1007/s00330-017-4866-0. Epub 2017 May 24.
Contrast media (CM) extravasation is a well-known complication of CT angiography (CTA). Our prospective randomized control study aimed to assess whether a four-phasic CM administration protocol reduces the risk of extravasation compared to the routinely used three-phasic protocol in coronary CTA.
Patients referred to coronary CTA due to suspected coronary artery disease were included in the study. All patients received 400 mg/ml iomeprol CM injected with dual-syringe automated injector. Patients were randomized into a three-phasic injection-protocol group, with a CM bolus of 85 ml followed by 40 ml of 75%:25% saline/CM mixture and 30 ml saline chaser bolus; and a four-phasic injection-protocol group, with a saline pacer bolus of 10 ml injected at a lower flow rate before the three-phasic protocol.
2,445 consecutive patients were enrolled (mean age 60.6 ± 12.1 years; females 43.6%). Overall rate of extravasation was 0.9% (23/2,445): 1.4% (17/1,229) in the three-phasic group and 0.5% (6/1,216) in the four-phasic group (p = 0.034).
Four-phasic CM administration protocol is easy to implement in the clinical routine at no extra cost. The extravasation rate is reduced by 65% with the application of the four-phasic protocol compared to the three-phasic protocol in coronary CTA.
• Four-phasic CM injection-protocol reduces extravasation rate by 65% compared to three-phasic. • The saline pacer bolus substantially reduces the risk of CM extravasation. • The implementation of four-phasic injection-protocol is at no cost.
对比剂(CM)外渗是 CT 血管造影(CTA)中已知的并发症。我们的前瞻性随机对照研究旨在评估四相 CM 给药方案是否比常规三相方案降低冠状动脉 CTA 中的外渗风险。
因疑似冠状动脉疾病而接受冠状动脉 CTA 的患者被纳入研究。所有患者均接受 400mg/ml 碘普罗胺 CM 注射,使用双注射器自动注射器。患者随机分为三相注射方案组,CM 推注量为 85ml,然后是 75%:25%盐水/CM 混合物 40ml 和 30ml 盐水推注;四相注射方案组,在三相方案前以较低流速注射 10ml 盐水先导。
共纳入 2445 例连续患者(平均年龄 60.6±12.1 岁;女性 43.6%)。总体外渗率为 0.9%(23/2445):三相组为 1.4%(17/1229),四相组为 0.5%(6/1216)(p=0.034)。
四相 CM 给药方案易于在临床常规中实施,且无需额外费用。与三相方案相比,四相方案在冠状动脉 CTA 中外渗率降低 65%。
四相 CM 注射方案与三相方案相比,降低外渗率 65%。
盐水先导可显著降低 CM 外渗风险。
四相注射方案的实施无需额外费用。